

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



# PRODUCT INFORMATION



### HDAC8 (human, recombinant)

Item No. 19380

#### **Overview and Properties**

Synonym: Histone Deacetylase 8

Source: Active recombinant C-terminal hexahistidine-tagged protein expressed in E. coli

**Amino Acids:** 2-377 (full length)

**Uniprot No.:** Q9BY41 Molecular Weight: 45.3 kDa

-80°C (as supplied); avoid freeze/thaw cycles by aliquoting protein Storage:

Stability: ≥6 months

**Purity:** ≥80% estimated by SDS-PAGE

Supplied in: 10 mM Tris, pH 7.5, containing 100 mM NaCl, 3 mM MgCl<sub>2</sub>, and 20% glycerol

Protein

Concentration: batch specific mg/ml Activity: batch specific U/ml Specific Activity: batch specific U/mg

**Unit Definition:** One unit is the amount of enzyme required to release 1 nmol/min acetate from 100  $\mu$ M

acetylated p53 peptide (Item No. 10010995) at 37°C in 25 mM Tris, pH 8.0, 137 mM

NaCl, 2.7 mM KCl, and 1 mM MgCl<sub>2</sub>.

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

#### **Images**





Figure 1: HDAC8 activity was inhibited by a known inhibit Trichostatin A.



Lane 1: MW Markers Lane 2: HDAC8 (2 μg) Lane 3: HDAC8 (4 µg)

Representative gel image shown; actual purity may vary between each batch.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/02/2021

CAYMAN CHEMICAL 1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM

## **PRODUCT INFORMATION**



#### Description

Histone deacetylases (HDACs) catalyze the deacetylation of core histones, resulting in tightening of nucleosomal integrity, restriction of the access of transcription factors, and suppression of transcription. HDACs also play an important role in mediating nuclear receptor functions by forming co-repressor complexes with nuclear receptors in the absence of ligands. They are also involved in mediating other transcription regulatory pathways by associating with transcription factors, such as E2F, TFIIF, NF-kB, p300, Stat3, p53, and the retinoblastoma (Rb) protein. HDAC8 is a Class I HDAC which is related to the yeast HDAC Rpd3. It is primarily localized to the nucleus with ubiquitous distribution throughout human cell lines and tissues. By modifying chromatin structure and other non-histone proteins, HDACs play important roles in controlling complex biological events, including cell development, differentiation, programmed cell death, angiogenesis, and inflammation. Considering these major roles, it is conceivable that dysregulation of HDACs and subsequent imbalance of acetylation and deacetylation may be involved in the pathogenesis of various diseases, including cancer and inflammatory diseases.

#### References

- 1. Lin, H.-Y., Chen, C.-S., Lin, S.-P., et al. Targeting histone deacetylase in cancer therapy. *Medicinal Research Reviews* **26(4)**, 397-413 (2006).
- 2. Huang, L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. *J. Cell. Physiol.* **39.1**, 611-616 (2006).

ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335